Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer that can be difficult to diagnose. It is most commonly found in elderly individuals and can be found in any area of the body. AFX is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration. Despite its rarity, it is important for doctors to be aware of the signs and symptoms of AFX, as early diagnosis and treatment are critical for successful outcomes.
Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer. It is a type of soft-tissue sarcoma, which is a cancer that develops in the connective tissues of the body. AFX is most commonly found in elderly individuals and can be found in any area of the body, although it is most commonly found on the head or neck. It is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration.
The most common sign of AFX is a rapidly growing, red-brown to yellow-brown papule or nodule. This lesion may be tender to the touch and may have a central ulceration. Other signs and symptoms of AFX may include itching, bleeding, and pain. The lesion may also be accompanied by a reddish-brown halo or a crusty, flaky surface.
Diagnosis of AFX begins with a physical examination. During the physical exam, the doctor will examine the lesion and may take a biopsy. A biopsy is a procedure in which a small sample of the lesion is removed and sent to a laboratory for further examination. The laboratory will examine the sample under a microscope and may order additional tests to confirm the diagnosis.
The primary treatment for AFX is surgical excision. This involves surgically removing the lesion and any surrounding tissue. In some cases, radiation therapy may be used to reduce the size of the lesion prior to surgery. In cases where the lesion is too large to be removed surgically, chemotherapy may be used to shrink the tumor.
Unfortunately, there is no known way to prevent AFX. However, it is important to practice sun safety and to avoid prolonged exposure to ultraviolet (UV) radiation. This includes wearing sunscreen and protective clothing when outdoors, avoiding tanning beds, and avoiding direct sun exposure during peak UV hours. Additionally, it is important to monitor any changes in the skin and to seek medical attention if any suspicious lesions are found.
Atypical fibroxanthoma (AFX) is a rare and aggressive form of skin cancer that can be difficult to diagnose. It is most commonly found in elderly individuals and can be found in any area of the body. AFX is characterized by a rapidly growing, red-brown to yellow-brown papule or nodule, often with a central ulceration. Early diagnosis and treatment are critical for successful outcomes, so it is important for doctors to be aware of the signs and symptoms of AFX. While there is no known way to prevent AFX, it is important to practice sun safety and to monitor any changes in the skin.
1.
Year in Review: Chronic Lymphocytic Leukemia
2.
According to a study, white Americans are overdiagnosing melanoma at an alarming rate.
3.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
4.
The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.
5.
Canine Cancer Vaccine: A Potential Resurrection? U.S. KK. Snubs Enertu.
1.
What Is Carboxyhemoglobin And How Can It Affect Your Health?
2.
Lu-177 Vipivotide in Prostate Cancer: A Breakthrough in Radioligand Therapy
3.
Unraveling the Mysteries of Coagulopathy: A Comprehensive Definition
4.
Machine Learning in Genomic Analysis for Early Lung Cancer Detection: Key Advances and Insights
5.
A New Perspective on Spherocytosis: Uncovering Innovative Treatments
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
2.
Navigating the Complexities of Ph Negative ALL - Part XIII
3.
Updates on the First Line Management of ALK+ NSCLC
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation